SGLT2 Inhibitors/Loop Diuretics Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both of your medicines can cause dehydration and kidney problems.
What might happen:
You may develop dehydration and kidney problems.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together, if you have any trouble with your kidneys, and if you are on a low salt diet. If you experience signs of dehydration such as dizziness, fainting, lightheadedness, weakness, (especially when you stand up) or kidney damage such as decreased urine production or swelling in the hands/feet, contact your doctor.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Wolf MS. Personal communication: Invokana - Concomitant use with diuretics. Janssen Scientific Affairs, LLC June 9, 2014.
- 2.Invokana (canagliflozin) US prescribing information. Janssen Pharmaceuticals, Inc. October, 2022.
- 3.Farxiga (dapagliflozin) US prescribing information. AstraZeneca Pharmaceuticals LP October, 2022.
- 4.Steglatro (ertugliflozin) US prescribing information. Merck & Co. October 2022.
- 5.Brenzavvy (bexagliflozin) US prescribing information. TheracosBio, LLC January, 2023.
- 6.Jardiance (empagliflozin) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. June, 2023.
- 7.USFood and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). available at: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM506772.pdf June 14, 2016.
- 8.Butler J, Usman MS, Filippatos G, Ferreira JP, Bohm M, Brueckmann M, Januzzi JL, Kaul S, Pina IL, Ponikowski P, Senni M, Sumin M, Verma S, Zaremba-Pechmann L, Pocock SJ, Packer M, Anker S. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial. JAMA Cardiol 2023 May 24.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.